- Home
- RIV vs GALT Comparison
RIV vs GALT Comparison
Compare RIV & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- GALT
- Stock Information
- Founded
- RIV 2015
- GALT 2000
- Country
- RIV United States
- GALT United States
- Employees
- RIV N/A
- GALT N/A
- Industry
- RIV Finance Companies
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- RIV Finance
- GALT Health Care
- Exchange
- RIV Nasdaq
- GALT Nasdaq
- Market Cap
- RIV 260.6M
- GALT 232.3M
- IPO Year
- RIV N/A
- GALT N/A
- Fundamental
- Price
- RIV $11.97
- GALT $4.75
- Analyst Decision
- RIV
- GALT Strong Buy
- Analyst Count
- RIV 0
- GALT 3
- Target Price
- RIV N/A
- GALT $6.00
- AVG Volume (30 Days)
- RIV 87.6K
- GALT 367.3K
- Earning Date
- RIV 01-01-0001
- GALT 11-12-2025
- Dividend Yield
- RIV 12.85%
- GALT N/A
- EPS Growth
- RIV N/A
- GALT N/A
- EPS
- RIV N/A
- GALT N/A
- Revenue
- RIV N/A
- GALT N/A
- Revenue This Year
- RIV N/A
- GALT N/A
- Revenue Next Year
- RIV N/A
- GALT N/A
- P/E Ratio
- RIV N/A
- GALT N/A
- Revenue Growth
- RIV N/A
- GALT N/A
- 52 Week Low
- RIV $9.63
- GALT $0.73
- 52 Week High
- RIV $12.43
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- RIV 38.85
- GALT 60.29
- Support Level
- RIV $11.92
- GALT $4.10
- Resistance Level
- RIV $12.03
- GALT $5.06
- Average True Range (ATR)
- RIV 0.08
- GALT 0.29
- MACD
- RIV 0.00
- GALT -0.05
- Stochastic Oscillator
- RIV 49.00
- GALT 56.25
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.